Skip to main content
TENAX THERAPEUTICS, INC. logo

TENAX THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · TENX ISIN · US88032L2097 LEI · 549300J03O6B1IJ2B606 US Manufacturing
Open in API
Filings indexed 938 across all filing types
Latest filing 2026-05-12 Share Issue/Capital Cha…
Country US United States of America
Listing US TENX

About TENAX THERAPEUTICS, INC.

http://www.tenaxthera.com/

Tenax Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing novel therapies for cardiovascular and pulmonary diseases. The company's primary drug candidate is TNX-103, an oral formulation of levosimendan, for the treatment of heart failure. The intravenous form of levosimendan is already approved in numerous countries for acute decompensated heart failure, providing an established safety profile. Additionally, Tenax is developing a formulation of imatinib mesylate, a kinase inhibitor, for the treatment of pulmonary arterial hypertension (PAH). The company's development strategy is guided by clinical insights into cardiopulmonary disorders and is led by a management team with extensive experience in the field.

Recent filings

Filing Released Lang Actions
S-8 - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
Share Issue/Capital Change Classification · 82% confidence The document is a Securities and Exchange Commission Form S-8 registration statement covering inducement stock option awards and restricted stock unit awards, which registers new shares for issuance under the company’s equity plans. This is not a financial report (10-K, 10-Q, etc.) nor a proxy or AGM material, but rather a regulatory filing that announces the registration and issuance of new shares. Under our taxonomy, this falls squarely into “Share Issue/Capital Change” (Code: SHA).
2026-05-12 English
10-Q - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-12 English
8-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)
Regulatory Filings Classification · 50% confidence The document is a Form 8-K current report filed with the SEC, reporting an earnings press release attached as Exhibit 99.1 and providing no substantive financial statements itself. It is under 5,000 characters and simply states that the press release is attached. Per the "menu vs meal" rule, this is not the earnings release itself but a regulatory announcement of it. It therefore falls into the catch-all Regulatory Filings category rather than an ER or IR report.
2026-05-12 English
Major Shareholding Notification 2026
Major Shareholding Notification
2026-05-09 English
Major Shareholding Notification 2026
Major Shareholding Notification
2026-05-07 English
Major Shareholding Notification 2026
Major Shareholding Notification
2026-05-07 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.